Patients

Providers

The Varicose Vein Market

More than 40 million people in the United States suffer from varicose veins*.

Almost 50% of varicose vein patients have a family history of varicose veins*

If both parents have varicose veins, the chances to develop the disease are close to 90%.

It is estimated that 41% of women over the age of 50 have varicose veins.

It is estimated that 50% of the US population over 50 years old have varicose veins.

For these patients, varicose veins can be much more than a cosmetic concern.

Women who are moderately overweight (BMI 25-29.9) have a 50% increased risk of developing varicose veins compared to women who are not overweight. Women with a BMI greater than 30 are three times as likely to develop varicose veins. (How many procedures done in the U.S?)

VascuLife vein treatment is a state of the art technology designed for endovenous laser ablation, EVLA, and maximizes outcomes without downtime. Insurance reimbursements for EVLA range from $1500 to $2300.

VascuLife** is:

An in-office procedure

Minimally invasive

Typically performed in less than 30 minutes

Minimal risk of unwanted side effects

Patients may return to normal activities immediately following surgery.

Superficial Veins

80 million Americans are suffering from varicose or spider veins also known as telangiectasias.

Spider veins are smaller in size, beginning as tiny red or blue capillaries that lie close to the surface of the skin and are easily visible. Spider veins are most commonly found on the thighs, calves, ankles or face, where they may be a cosmetic concern. Not all spider veins require treatment.

*Sources: healthyveins(dot)org. phlebology(dot)org**VascuLife is not available in Canada

Alma’s Beauty Rejuve and Harmony XL PRO can offer a non-invasive alternative to treating these superficial vein types with a special 1064nm Long Pulsed Nd:YAG laser.